NCT03212040 is a NA clinical trial of needle biopsy in Breast Biopsy, sponsored by University Hospital Tuebingen.

Who is sponsoring NCT03212040?

NCT03212040 is sponsored by University Hospital Tuebingen.

What drugs are being tested in NCT03212040?

Interventions in NCT03212040: needle biopsy.

What condition does NCT03212040 study?

NCT03212040 studies Breast Biopsy.

Is NCT03212040 still recruiting?

NCT03212040 is currently completed. Last updated 22 July 2024.

Last reviewed 2024-07-22 · How we verify

NCT03212040

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

14 g vs. 16 g in Breast Biopsy

Completed NA Last updated 22 July 2024

What this trial tests

NA trial testing needle biopsy in Breast Biopsy in 186 participants. Completed in 7 June 2018.

Timeline

5 December 2011

Primary endpoint
18 February 2013

7 June 2018

Quick facts

Lead sponsor	University Hospital Tuebingen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	186
Start date	5 December 2011
Primary completion	18 February 2013
Estimated completion	7 June 2018
Sites	1 location across Germany

Drugs / interventions tested

needle biopsy

Conditions studied

Breast Biopsy — all drugs for Breast Biopsy →

Sponsor

University Hospital Tuebingen

Who can join

Adults 18 to 80, female only, with Breast Biopsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Comparison of biopsy needles with a different diameter, i.e. 14 vs 16 gauge, used for breast biopsies

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of needle biopsy

Trials testing the same drug.

NCT01259089 — Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer · Phase 1, PHASE2 · completed
NCT00482755 — Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery · Phase 2 · completed
NCT00665457 — Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery · Phase 2 · terminated

Other University Hospital Tuebingen trials

Trials by the same sponsor.

NCT07378670 — DEfeating PEnile CAncer-2 · NA · recruiting
NCT07276503 — Verification of a New Predictive Delirium Score in Adults With Elective Cardiac Valve or Bypass Surgery With Perioperati · not yet recruiting
NCT07411365 — Dual-task Cognitive-motor Telerehabilitation in Persons With PD-MCI · NA · not yet recruiting
NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
NCT07378891 — Artificial-Intelligence-based Early Detection of Diabetic Retinopathy (FUNDUS AI) · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03212040 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Tuebingen
Last refreshed: 22 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03212040.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing